The laboratory is interested on biomolecular and biopharmaceutical engineering aiming the investigation, analysis, and integration of genomic and proteomic data towards the design of therapeutic proteins. This will lead us to guide protein engineering through molecular medicine and bio-nanotechnology in a mid- to long-term timeframe. At the center of our biopharmaceutical development we aim at rational antibody engineering as our approach to validate our theoretical concepts. We consider the use of intracellular and extracellular small-domain antibodies to be exemplary in our rational protein engineering strategies. The interest in protein therapeutics may stem the discovery and development of new leads for biopharmaceuticals in the area of infectious diseases, cancer and neurological problems. The focus on the discovery and development of a new class of therapeutic antibodies and efficient display technologies may allow the rapid identification of binding proteins with high affinity and specificity. In addition , we plan to adapt our antibody domain platform and synthetic biology approaches to develop CAR-T receptors based on SynNotch engineered cells that may have even broader applications as general delivery agents that can locally produce any genetically encoded bio-therapeutic that has systemic toxicity. Development of better characterization assays and monitoring of antibody therapy in patients, including immunogenicity and pharmacokinetics to biosimilars is current to our work. The evaluation of quality, efficacy and safety attributes of biosimilar antibodies and fusion proteins is at the centre of our clinical collaborations.